Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group.
Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, Rouphael N, Evans SR, Fowler VG, Hamasaki T, Patel R, Komarow L, Baum K, Souli M, Schwager N, Bonomo RA, Doi Y; Antibacterial Resistance Leadership Group. Satlin MJ, et al. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S305-S313. doi: 10.1093/cid/ciad547. Clin Infect Dis. 2023. PMID: 37843118 Free PMC article.
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.
Doernberg SB, Arias CA, Altman DR, Babiker A, Boucher HW, Creech CB, Cosgrove SE, Evans SR, Fowler VG, Fritz SA, Hamasaki T, Kelly BJ, Leal SM, Liu C, Lodise TP, Miller LG, Munita JM, Murray BE, Pettigrew MM, Ruffin F, Scheetz MH, Shopsin B, Tran TT, Turner NA, Williams DJ, Zaharoff S, Holland TL; Antibacterial Resistance Leadership Group. Doernberg SB, et al. Among authors: zaharoff s. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S295-S304. doi: 10.1093/cid/ciad565. Clin Infect Dis. 2023. PMID: 37843115 Free PMC article. Review.
Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.
Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Wall A, Wiegand K, Chambers HF; Antibacterial Resistance Leadership Group. Lodise TP, et al. Among authors: zaharoff s. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093622. doi: 10.1128/aac.00936-22. Epub 2022 Nov 17. Antimicrob Agents Chemother. 2022. PMID: 36394326 Free PMC article. Clinical Trial.
Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.
Lodise TP, O'Donnell JN, Raja S, Guptill JT, Zaharoff S, Schwager N, Fowler VG Jr, Beresnev T, Wall A, Wiegand K, Serti Chrisos E, Balevic S, Chambers HF; Antibacterial Resistance Leadership Group. Lodise TP, et al. Among authors: zaharoff s. Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0093522. doi: 10.1128/aac.00935-22. Epub 2022 Nov 17. Antimicrob Agents Chemother. 2022. PMID: 36394316 Free PMC article. Clinical Trial.
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Turner NA, et al. Among authors: zaharoff s. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. Trials. 2022. PMID: 35578360 Free PMC article.
Determination of plasma protein binding of dalbavancin.
Turner NA, Xu A, Zaharoff S, Holland TL, Lodise TP. Turner NA, et al. Among authors: zaharoff s. J Antimicrob Chemother. 2022 Jun 29;77(7):1899-1902. doi: 10.1093/jac/dkac131. J Antimicrob Chemother. 2022. PMID: 35488862 Free PMC article.